Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKS NASDAQ:FGEN NASDAQ:INSM NASDAQ:LEGN NASDAQ:MOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$29.80-0.8%$29.40$25.17▼$36.45$4.92B0.542.13 million shs2.08 million shsFGENFibroGen$10.83+1.1%$11.40$4.50▼$21.94$43.80M0.7626,575 shs14,346 shsINSMInsmed$159.66-0.3%$147.38$60.40▼$168.21$33.75B1.031.96 million shs1.11 million shsLEGNLegend Biotech$31.86+0.6%$33.69$27.34▼$47.79$5.88B0.231.43 million shs1.48 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes-0.80%-1.52%+7.16%+14.05%+7.00%FGENFibroGen+1.12%+4.34%-12.52%+45.37%+35.38%INSMInsmed-0.29%-3.68%+13.23%+53.59%+121.93%LEGNLegend Biotech+0.60%-0.31%-3.10%-26.52%-27.51%MORMorphoSys0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$29.80-0.8%$29.40$25.17▼$36.45$4.92B0.542.13 million shs2.08 million shsFGENFibroGen$10.83+1.1%$11.40$4.50▼$21.94$43.80M0.7626,575 shs14,346 shsINSMInsmed$159.66-0.3%$147.38$60.40▼$168.21$33.75B1.031.96 million shs1.11 million shsLEGNLegend Biotech$31.86+0.6%$33.69$27.34▼$47.79$5.88B0.231.43 million shs1.48 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes-0.80%-1.52%+7.16%+14.05%+7.00%FGENFibroGen+1.12%+4.34%-12.52%+45.37%+35.38%INSMInsmed-0.29%-3.68%+13.23%+53.59%+121.93%LEGNLegend Biotech+0.60%-0.31%-3.10%-26.52%-27.51%MORMorphoSys0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 3.00Buy$42.8343.74% UpsideFGENFibroGen 2.00Hold$43.00297.05% UpsideINSMInsmed 2.86Moderate Buy$152.88-4.25% DownsideLEGNLegend Biotech 2.73Moderate Buy$66.56108.90% UpsideMORMorphoSys 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest FGEN, ALKS, INSM, LEGN, and MOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025FGENFibroGenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/25/2025INSMInsmedWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/25/2025LEGNLegend BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/23/2025ALKSAlkermesPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$38.00 ➝ $45.0010/22/2025ALKSAlkermesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$45.00 ➝ $47.0010/22/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral10/22/2025ALKSAlkermesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/20/2025INSMInsmedWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$171.0010/17/2025LEGNLegend BiotechJohnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$60.0010/17/2025LEGNLegend BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$75.00 ➝ $60.0010/14/2025INSMInsmedUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$140.00 ➝ $194.00(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.56B3.16$2.65 per share11.24$9.05 per share3.29FGENFibroGen$29.62M1.48N/AN/A($50.89) per share-0.21INSMInsmed$363.71M92.79N/AN/A$1.60 per share99.79LEGNLegend Biotech$627.24M9.38N/AN/A$5.70 per share5.59MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0814.3321.751.6123.15%24.86%17.14%10/28/2025 (Estimated)FGENFibroGen-$47.58M-$0.38N/AN/AN/A-3.86%N/A-27.34%11/11/2025 (Estimated)INSMInsmed-$913.77M-$5.71N/AN/AN/A-259.82%-195.37%-49.49%10/30/2025 (Estimated)LEGNLegend Biotech-$177.03M-$0.88N/AN/AN/A-40.83%-32.00%-20.07%11/11/2025 (Estimated)MORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/ALatest FGEN, ALKS, INSM, LEGN, and MOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025FGENFibroGen-$4.01N/AN/AN/A$1.64 millionN/A11/11/2025Q3 2025LEGNLegend Biotech-$0.08N/AN/AN/A$277.91 millionN/A10/30/2025Q3 2025INSMInsmed-$1.35N/AN/AN/A$114.33 millionN/A10/28/2025Q3 2025ALKSAlkermes$0.41N/AN/AN/A$355.23 millionN/A8/11/2025Q2 2025FGENFibroGen-$2.25-$3.38-$1.13-$1.88$2.88 million$1.30 million8/11/2025Q2 2025LEGNLegend Biotech-$0.22-$0.34-$0.12-$0.34$237.49 million$255.06 million8/7/2025Q2 2025INSMInsmed-$1.30-$1.70-$0.40-$1.70$104.06 million$107.42 million7/29/2025Q2 2025ALKSAlkermes$0.42$0.52+$0.10$0.52$343.20 million$390.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.232.85FGENFibroGenN/A1.041.02INSMInsmed0.456.686.33LEGNLegend Biotech0.304.714.57MORMorphoSys4.981.381.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%FGENFibroGen72.71%INSMInsmedN/ALEGNLegend Biotech70.89%MORMorphoSys18.38%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%FGENFibroGen3.07%INSMInsmed3.00%LEGNLegend Biotech0.02%MORMorphoSys0.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes1,800165.08 million157.82 millionOptionableFGENFibroGen5704.04 million3.92 millionOptionableINSMInsmed1,271211.38 million205.03 millionOptionableLEGNLegend Biotech2,609184.57 million184.53 millionOptionableMORMorphoSys730150.62 million150.55 millionNot OptionableFGEN, ALKS, INSM, LEGN, and MOR HeadlinesRecent News About These CompaniesMyelofibrosis Market Overview: Epidemiology, Therapies, and Key Players include AbbVie, Morphosys, Geron, Bristol Myers Squibb, Kartos Therapeutics, Karyopharm Therapeutics, NS ...October 7, 2025 | theglobeandmail.comMorphoSys takeover delivers phase 3 win for NovartisAugust 11, 2025 | pharmaphorum.comPNovartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune diseaseAugust 11, 2025 | biopharmadive.comBMaxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development OfficerJune 17, 2025 | finance.yahoo.comEssential Thrombocythemia Market Set for Significant Growth Across 7MM | DelveInsightMarch 21, 2025 | theglobeandmail.comRoyalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receiptsFebruary 12, 2025 | seekingalpha.comVIDEO: Triplet therapy improved PFS in relapsed, refractory follicular lymphomaJanuary 15, 2025 | healio.comHNovartis closing Morphosys facilities, laying off 330 workersJanuary 8, 2025 | bioworld.comBSwiss pharma giant Novartis to close biotech firm MorphosysDecember 20, 2024 | swissinfo.chSNovartis to shut MorphSys sites amid pelabresib delayDecember 20, 2024 | thepharmaletter.comTNovartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 JobsDecember 19, 2024 | biospace.comBNovartis sheds MorphoSys staff, sites after pelabresib delayDecember 19, 2024 | pharmaphorum.comPNovartis shutters MorphoSys sites, lays off staffDecember 19, 2024 | finance.yahoo.comSome 330 jobs hit as Novartis closes Morphosys, WiWo reportsDecember 19, 2024 | reuters.comNovartis raises mid-term sales guidanceNovember 21, 2024 | seekingalpha.comNovartis: launch of Morphosys drug by could be 2027 or laterNovember 21, 2024 | reuters.comIdiopathic Membranous Nephropathy Market Size is estimated to grow with a significant CAGR during the study period (2020-2034).November 14, 2024 | theglobeandmail.comEagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial OfficerNovember 12, 2024 | manilatimes.netMModerna said to shuffle sales leadership; Vertex records first Casgevy saleNovember 6, 2024 | biopharmadive.comBTango stock plunges 28% amid pipeline updates, Q3 earnings reportNovember 6, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Rocket Lab USA Receives Wall Street Validation: Time to Buy?By Ryan Hasson | October 16, 2025Why the Precious Metal Nobody Talks About Could Be Your Best BetBy Jordan Chussler | October 4, 20253 Fintech Stocks That Are Set to Rise as Rates FallBy Gabriel Osorio-Mazilli | October 6, 2025FGEN, ALKS, INSM, LEGN, and MOR Company DescriptionsAlkermes NASDAQ:ALKS$29.80 -0.24 (-0.80%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$29.92 +0.13 (+0.42%) As of 10/24/2025 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.FibroGen NASDAQ:FGEN$10.83 +0.12 (+1.12%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$10.86 +0.03 (+0.23%) As of 10/24/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Insmed NASDAQ:INSM$159.66 -0.46 (-0.29%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$159.25 -0.41 (-0.26%) As of 10/24/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Legend Biotech NASDAQ:LEGN$31.86 +0.19 (+0.60%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$32.30 +0.44 (+1.37%) As of 10/24/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 10/24/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
